Status:
COMPLETED
Drug Interaction Study With a Potential Alzheimer's Disease Compound
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Alzheimer Disease
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine whether BMS-708163 will effect the pharmacokinetics of the commonly prescribed medicines midazolam, warfarin, caffeine,omeprazole and dextromethorphan
Eligibility Criteria
Inclusion
- Healthy male subjects
- 18-45 yrs old inclusive
Exclusion
- Women
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00726726
Start Date
August 1 2008
End Date
October 1 2008
Last Update
November 5 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bristol-Myers Squibb Clinical Pharmacology Unit
Hamilton, New Jersey, United States, 08690